Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C31H33N5O2S |
| Molecular Weight | 539.691 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=CC=C(C=C23)C4=CSC(=N4)C5=CC=CC=C5)=C1C
InChI
InChIKey=QDWKGEFGLQMDAM-ULJHMMPZSA-N
InChI=1S/C31H33N5O2S/c1-5-36(6-2)15-14-32-30(38)28-19(3)26(33-20(28)4)17-24-23-16-22(12-13-25(23)34-29(24)37)27-18-39-31(35-27)21-10-8-7-9-11-21/h7-13,16-18,33H,5-6,14-15H2,1-4H3,(H,32,38)(H,34,37)/b24-17-
Amcasertib is an orally administered investigational agent designed to inhibit cancer stemness pathways, including Nanog, by targeting stemness kinases. Amcasertib is undergoing multiple Phase I and Phase II studies as monotherapy and combination therapy for treating a range of tumor types.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Q9H9S0 Gene ID: 79923.0 Gene Symbol: NANOG Target Organism: Homo sapiens (Human) |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
5.7 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31900032 |
0.4 mg single, oral dose: 0.4 mg route of administration: Oral experiment type: SINGLE co-administered: |
PEMAFIBRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
20 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31900032 |
0.4 mg single, oral dose: 0.4 mg route of administration: Oral experiment type: SINGLE co-administered: |
PEMAFIBRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02232620
Gastrointestinal Stromal Tumors: BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C129825
Created by
admin on Mon Mar 31 21:50:30 GMT 2025 , Edited by admin on Mon Mar 31 21:50:30 GMT 2025
|
||
|
NCI_THESAURUS |
C1404
Created by
admin on Mon Mar 31 21:50:30 GMT 2025 , Edited by admin on Mon Mar 31 21:50:30 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
25190990
Created by
admin on Mon Mar 31 21:50:30 GMT 2025 , Edited by admin on Mon Mar 31 21:50:30 GMT 2025
|
PRIMARY | |||
|
1129403-56-0
Created by
admin on Mon Mar 31 21:50:30 GMT 2025 , Edited by admin on Mon Mar 31 21:50:30 GMT 2025
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
GLY8ABW25V
Created by
admin on Mon Mar 31 21:50:30 GMT 2025 , Edited by admin on Mon Mar 31 21:50:30 GMT 2025
|
PRIMARY | |||
|
CD-142
Created by
admin on Mon Mar 31 21:50:30 GMT 2025 , Edited by admin on Mon Mar 31 21:50:30 GMT 2025
|
PRIMARY | |||
|
CHEMBL3707349
Created by
admin on Mon Mar 31 21:50:30 GMT 2025 , Edited by admin on Mon Mar 31 21:50:30 GMT 2025
|
PRIMARY | |||
|
100000181435
Created by
admin on Mon Mar 31 21:50:30 GMT 2025 , Edited by admin on Mon Mar 31 21:50:30 GMT 2025
|
PRIMARY | |||
|
10119
Created by
admin on Mon Mar 31 21:50:30 GMT 2025 , Edited by admin on Mon Mar 31 21:50:30 GMT 2025
|
PRIMARY | |||
|
C104745
Created by
admin on Mon Mar 31 21:50:30 GMT 2025 , Edited by admin on Mon Mar 31 21:50:30 GMT 2025
|
PRIMARY | |||
|
DB14866
Created by
admin on Mon Mar 31 21:50:30 GMT 2025 , Edited by admin on Mon Mar 31 21:50:30 GMT 2025
|
PRIMARY |
ACTIVE MOIETY